FDA's Combo Product Consultations To Be Streamlined
This article was originally published in The Pink Sheet Daily
Executive Summary
Internal assessment finds inter-center collaboration stymied by issues ranging from IT compatibility to resource reimbursement, but FDA says it has a five-point plan to improve the process.
You may also be interested in...
Combo Product Safety: US FDA Rule On Postmarket Reporting Nears Finalization
Industry is eagerly awaiting guidance on combination products, and after seven years the postmarketing reg may be at top of the agency’s queue.
FDA 'Intercenter Institutes' Legislation Headed For Senate Mark-Up
FDA would be directed to test the concept of joint drug/device/diagnostic reviews in at least one therapeutic area; idea of further integrating medical product reviews is also part of Vice President’s cancer 'moonshot.'
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.